Citations

Clear

3042 citation(s) found for "Kumar, S".

Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
Pal, Krishnendu , Pletnev, Alexandre A., Dutta, Shamit K., Wang, Enfeng , Zhao, Ruizhi , Baral, Aradhita, Yadav, Vinod Kumar , Aggarwal, Suruchi , Krishnaswamy, Soundararajan, Alkharfy, Khalid M. , Chowdhury, Shantanu , Spaller, Mark R., Mukhopadhyay, Debabrata , Pal, Krishnendu

Mayo Clinic

Molecular Cancer Therapeutics | August 15, 2014 | Volume: 13 | Issue: 10 | Pages: 2264-2275

10.1158/1535-7163.mct-14-0291 | PMID 25125675 Get It

Abstract Endoglin, a 180-kDa disulfide-linked homodimeric transmembrane receptor protein mostly expressed in tumor-associated endothelial cells, is an endogenous binding partner of GAIP-interacting protein, C terminus (GIPC). Endoglin functions as a coreceptor of TβRII that binds TGFβ and is important for vascular development, and consequently has become a compelling target for antiangiogenic therapies. A few recent studies in gastrointestinal stromal tumor (GIST), breast cancer, and ovarian cancer, however, suggest that endoglin is upregulated in tumor cells and is associated with poor prognosis. These findings indicate a broader role of endoglin in tumor biology, beyond angiogenic effects. The goal of our current study is to evaluate the effects of targeting endoglin in pancreatic cancer both in vitro and in vivo. We analyzed the antiproliferative effect of both RNAi-based and peptide ligand-based inhibition of endoglin in pancreatic cancer cell lines, the latter yielding a GIPC PDZ domain-targeting lipopeptide with notable antiproliferative activity. We further demonstrated that endoglin inhibition induced a differentiation phenotype in the pancreatic cancer cells and sensitized them against conventional chemotherapeutic drug gemcitabine. Most importantly, we have demonstrated the antitumor effect of both RNAi-based and competitive inhibitor–based blocking of endoglin in pancreatic cancer xenograft models in vivo. To our knowledge, this is the first report exploring the effect of targeting endoglin in pancreatic cancer cells. Mol Cancer Ther; 13(10); 2264–75. ©2014 AACR.
Abstract 1882: Role of cystathionine beta-synthase in ovarian cancer growth, metastasis and drug sensitivity.
Saha, Sounik, Giri, Karuna, Nair, K.S., Jennings, Nicholas B. , Bhattacharyya, Sanjib , Lanza, Ian R. , Kumar, Rakesh , Sood, Anil K. , Bhattacharya, Resham , Mukherjee, Priyabrata

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 1882-1882

10.1158/1538-7445.am2013-1882 Get It

Abstract Hydrogen sulfide (H2S), the third gasotransmitter, has recently attracted a lot of attention for its cytoprotective action and role in angiogenesis. Dysregulation of the major enzymes which produces H2S namely, cystathionine beta synthase (CBS), cystathionine gamma lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST) have also been implicated in a large number of pathological conditions that range from neurological disorders to cardiovascular diseases. Surprisingly, studies on the role of these enzymes in cancer is scarce, especially, that of CBS. Relapse with a drug resistant and aggressive phenotype is a common occurrence in ovarian cancer with an overall 5-year survival of approximately 30%. Here we report that, CBS, a key enzyme required for sulphur amino acid metabolism, plays a critical role in promoting ovarian cancer growth, metastasis and drug resistance. Overexpression of CBS was observed in a majority of ovarian cancer cell lines utilized in our study compared to normal ovarian surface epithelial cells. Silencing CBS in A2780 cells using siRNA or a CBS-specific inhibitor, aminooxyacetic acid reduced proliferation of ovarian cancer cells by dramatically reducing total glutathione levels, H2S levels and thereby enhancing oxidative stress. Downregulation of CBS reduced activation of NF-kB and upregulated p53 protein levels thereby inactivating the antioxidant network of the cells. A deeper insight into the intracellular localization of CBS by confocal fluorescence microscopy demonstrated a mitochondria specific distribution and silencing CBS caused mitochondrial superoxide accumulation that resulted in decreased mitochondrial respiration, reduced ATP production and increased ADP-to-ATP ratio. Furthermore, silencing CBS, augmented the activity of cisplatin in vitro in A2780 cells and in vivo in an orthotopic model of advanced ovarian cancer. Nanoliposomal delivery of CBS siRNA significantly reduced the number of tumor nodules in a chemoresistant orthotopic mouse model of ovarian cancer. To our knowledge, this is the first study demonstrating the importance of CBS in ovarian cancer progression and drug resistance and therefore is a viable target for future anti-cancer therapies. Citation Format: Sounik Saha, Sanjib Bhattacharyya, Karuna Giri, Ian R. Lanza, K. Sreekumar Nair, Nicholas B. Jennings, Rakesh Kumar, Anil K. Sood, Resham Bhattacharya, Priyabrata Mukherjee. Role of cystathionine beta-synthase in ovarian cancer growth, metastasis and drug sensitivity. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1882. doi:10.1158/1538-7445.AM2013-1882
CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation
Kumar, Y. Shiva, Kung, Simon , Shinozaki, Gen , Kumar, Yingying

Mayo Clinic

Journal of Psychopharmacology | August 14, 2014 | Volume: 28 | Issue: 12 | Pages: 1143-1148

10.1177/0269881114543720 | PMID 25122046 Get It

Recently, a FDA Safety Communication warned of a dose-dependent risk for QTc prolongation with citalopram, which is metabolized by CYP2C19 of the cytochrome P450 system. We investigate associations between citalopram and escitalopram dose, serum concentration, CYP2C19 phenotype, and QTc. We undertook a retrospective chart review of citalopram or escitalopram patients with the inclusion criteria of consistent medication dose, CYP2C19 phenotype (extensive metabolizers [EM], intermediate metabolizers [IM], poor metabolizers [PM]), and QTc interval on ECG. We further identified 42 citalopram users with citalopram serum concentration measurements and ECG. Regression and one-way ANOVA were used to examine the relationship between citalopram dose, citalopram serum concentration, CYP2C19 phenotype, and QTc interval. Of 75 citalopram patients, the EM group had significantly shorter QTc intervals than a combined IM+PM group (427.1±23.6 ms vs. 440.1±26.6 ms, one-tailed t-test, p=0.029). In the 80 escitalopram cohort, there was no significant difference in QTc between phenotype groups. There was no statistical correlation between citalopram ( p=0.62) or escitalopram ( p=0.30) dose and QTc. QTc was not associated with citalopram serum level ( p=0.45). In contrast to the FDA warning, this study found no association between citalopram/escitalopram dose and QTc. However, PM of the drug tended to have longer QTc intervals. Our findings suggest cytochrome P450 genotyping in select patients may be helpful to guide medication optimization while limiting harmful effects.
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Morice, William G. , Timm, Michael, Dispenzieri, Angela , Lacy, Martha Q. , Kapoor, Prashant , Kumar, Shaji , Gonsalves, Wilson I. , Morice, William George , Rajkumar, S. Vincent , Gupta, Vinay Kumar , Buadi, Francis K. , Singh, Preet Paul , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

British Journal of Haematology | August 12, 2014 | Volume: 167 | Issue: 4 | Pages: 500-505

10.1111/bjh.13067 | PMID 25113422 Get It

Summary The presence of clonal circulating plasma cells (c PC s) remains a marker of high‐risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for c PC s by multi‐parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal c PC s than those in a plateau ( P < 0·001). None of the patients in CR had any clonal c PC s detected. Among patients whose disease was in a plateau, the presence of clonal c PC s predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 c PC s predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk‐adapted treatment approach in MM patients with actively relapsing disease.
Promoter-proximal transcription factor binding is transcriptionally active when coupled with nucleosome repositioning in immediate vicinity
Yadav, Vinod Kumar , Thakur, Ram Krishna, Eckloff, Bruce W., Baral, Aradhita, Singh, Ankita, Halder, Rashi , Kumar, Akinchan, Alam, Mohammad P., Kundu, Tapas K. , Pandita, Raj K., Pandita, Tej K. , Wieben, Eric D. , Chowdhury, Shantanu , Eckloff, Bruce

Mayo Clinic

Nucleic Acids Research | August 1, 2014 | Volume: 42 | Issue: 15 | Pages: 9602-9611

10.1093/nar/gku596 | PMID 25081206 Get It

Abstract Previous studies have analyzed patterns of transcription, transcription factor (TF) binding or mapped nucleosome occupancy across the genome. These suggest that the three aspects are genetically connected but the cause and effect relationships are still unknown. For example, physiologic TF binding studies involve many TFs, consequently, it is difficult to assign nucleosome reorganization to the binding site occupancy of any particular TF. Therefore, several aspects remain unclear: does TF binding influence nucleosome (re)organizations locally or impact the chromatin landscape at a more global level; are all or only a fraction of TF binding a result of reorganization in nucleosome occupancy and do all TF binding and associated changes in nucleosome occupancy result in altered gene expression? With these in mind, following characterization of two states (before and after induction of a single TF of choice) we determined: (i) genomic binding sites of the TF, (ii) promoter nucleosome occupancy and (iii) transcriptome profiles. Results demonstrated that promoter-proximal TF binding influenced expression of the target gene when it was coupled to nucleosome repositioning at or close to its binding site in most cases. In contrast, only in few cases change in target gene expression was found when TF binding occurred without local nucleosome reorganization.
Cardiovascular Risk and Acute Coronary Syndrome in Giant Cell Arteritis: A Population‐Based Retrospective Cohort Study
Udayakumar, Prabhu D., Crowson, Cynthia S. , Warrington, Kenneth J. , Matteson, Eric L. , Chandran, Arun Kumar , Warrington, Kenneth J

Mayo Clinic

Arthritis Care & Research | July 29, 2014 | Volume: 67 | Issue: 3 | Pages: 396-402

10.1002/acr.22416 | PMID 25074472 Get It

Objective To assess the occurrence of acute coronary syndrome (ACS) in patients with giant cell arteritis (GCA) compared to subjects without GCA. Methods We retrospectively reviewed a population‐based incidence cohort of Olmsted County, Minnesota residents with GCA diagnosed in 1950–2009. We compared this cohort with a cohort of patients without GCA of similar age, sex, and calendar year from the same population. Results The study included 245 patients with GCA and 245 non‐GCA subjects. The mean ± SD Framingham cardiovascular risk score was 30% ± 19% in GCA patients and 34% ± 23% in non‐GCA subjects ( P = 0.096) at the incidence/index date. Diabetes mellitus was significantly less common in GCA patients than non‐GCA subjects at the index date. The mean high‐density lipoprotein was higher and triglycerides were lower, with fewer patients taking lipid‐lowering medications in the GCA cohort compared to the non‐GCA cohort at the index date. During followup, no difference between the 2 cohorts was noted in the overall rate of ACS events (hazard ratio 0.74, 95% confidence interval 0.44–1.26). Overall thrombosis in myocardial infarction scores were similar in both cohorts. Revascularization procedures were done less frequently in GCA than in non‐GCA subjects (19% versus 50%; P = 0.015). Post‐ACS hospital length of stays and complications were similar in both cohorts. Conclusion Multiple cardiovascular risk factors are less atherogenic at incidence of GCA. There is no overall increased risk of ACS in patients with GCA.
Cost‐effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma
Pandya, Chintan , Hashmi, Shahrukh K. , Khera, Nandita , Dispenzieri, Angela , Siddiqui, Mustaqeem , Noyes, Katia , Kumar, Shaji , Gertz, Morie A. , Hogan, William J. , Dispenzieri, Angela , Siddiqui, Mustaqeem A

Mayo Clinic

Clinical Transplantation | July 17, 2014 | Volume: 28 | Issue: 10 | Pages: 1084-1091

10.1111/ctr.12421 | PMID 25040732 Get It

AbstractBackgroundAutologous stem cell transplant (ASCT) is the current standard of care for most patients with multiple myeloma (MM) who are transplant eligible, yet the timing ofASCTis disputed due to a similar overall (OS) and progression‐free survival with an earlyASCT(eASCT) or a delayedASCT(dASCT) approach.ObjectiveWe developed a decision analytic model to perform cost‐effectiveness analysis of the two commonly used treatment strategies forMM.MethodsData on disease progression and treatment effectiveness came from 2001 to 2008 cohort treated at the Mayo Clinic and from published studies. Cost analysis was performed from a third‐party payer perspective.ResultsThe Consumer Price Index adjusted 2012 costs ofeASCTanddASCTwere $249 236 and $262 610, respectively.eASCTcohort had a benefit of 1.96 quality‐adjusted life years (QALYs), 0.23 QALYs more thandASCT, implying thateASCTis preferred (dominant) overdASCT. The most critical variables in one‐way sensitivity analysis were treatment‐related mortality and OS associated witheASCTstrategy.ConclusionsWe conclude thateASCTcould potentially be a relatively cost‐effective treatment option for appropriate patients with MM, and these results would help patients, providers, and payers in decision making for timing of ASCT.
Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta‐analysis
Javed, Asma , Jumean, Marwan , Murad, M. Hassan , Okorodudu, Daniel, Kumar, Seema , Sochor, Ondřej , Lopez‐Jimenez, Francisco, Somers, Virend K. , López-Jiménez, Francisco , Murad, M Hassan

Mayo Clinic

Pediatric Obesity | June 25, 2014 | Volume: 10 | Issue: 3 | Pages: 234-244

10.1111/ijpo.242 | PMID 24961794 Get It

SummaryBackgroundThe ideal means of identifying obesity in children and adolescents has not been determined although body mass index (BMI) is the most widely used screening tool.ObjectiveWe performed a systematic review and meta‐analysis of studies assessing the diagnostic performance of BMI to detect adiposity in children up to 18 years.MethodsData sources were EMBASE, MEDLINE, Cochrane, Database of Systematic Reviews Cochrane CENTRAL, Web of Science and SCOPUS up to March 2013. Studies providing measures of diagnostic performance of BMI and using body composition technique for body fat percentage measurement were included.ResultsThirty‐seven eligible studies that evaluated 53 521 patients, with mean age ranging from 4 to 18 years were included in the meta‐analysis. Commonly used BMI cut‐offs for obesity showed pooled sensitivity to detect high adiposity of 0.73 (confidence interval [CI] 0.67–0.79), specificity of 0.93 (CI 0.88–0.96) and diagnostic odds ratio of 36.93 (CI 20.75–65.71). Males had lower sensitivity. Moderate heterogeneity was observed (I2 = 48%) explained in meta‐regression by differences across studies in race, BMI cut‐off, BMI reference criteria (Center for Disease Control vs. International Obesity Task Force) and reference standard method assessing adiposity.ConclusionBMI has high specificity but low sensitivity to detect excess adiposity and fails to identify over a quarter of children with excess body fat percentage.
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Rajkumar, S. Vincent , Dispenzieri, Angela , Lacy, Martha Q. , Kapoor, Prashant , Dingli, David , Lust, John A., Zeldenrust, Steven R., Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Rajkumar, S Vincent , Gonsalves, Wilson I. , Go, Ronald S. , Gupta, Vinay Kumar , Singh, Preet Paul , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | June 24, 2014 | Volume: 124 | Issue: 6 | Pages: 907-912

10.1182/blood-2014-03-565051 | PMID 24957143 Get It

Key Points Survival of patients with primary plasma cell leukemia has improved in recent years, but is still inferior to those patients with multiple myeloma. This survival benefit appears to be mainly in patients older than 65 years of age.
Clinical Reasoning: A 55-year-old man with weight loss, ataxia, and foot drop
Flanagan, Eoin P. , Kumar, Neeraj , Krecke, Karl N. , Katz, Brian, Pittock, Sean J. , Leep Hunderfund, Andrea N, Katz, Brian S, Hunderfund, Andrea N. Leep , Murray, Joseph A. , Pittock, S J , Flanagan, E P

Mayo Clinic

Neurology | June 17, 2014 | Volume: 82 | Issue: 24 | Pages: No page available

10.1212/wnl.0000000000000525 | PMID 24960835 Get It